Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb study investigating the efficacy of GRC 6211 for the treatment of neuropathic pain and osteoarthritis

Next Previous
Trial Profile

Phase IIb study investigating the efficacy of GRC 6211 for the treatment of neuropathic pain and osteoarthritis

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2008

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GRC 6211 (Primary)
  • Indications Musculoskeletal pain; Neuropathic pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals S.A.

Most Recent Events

  • 24 Oct 2008 Clinical development of GRC 6211 in osteoarthritis has been suspended.
  • 05 Jun 2007 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top